21:40 , Jul 11, 2019 |  BC Innovations  |  Distillery Therapeutics

Treating asthma, allergic diseases with mAbs against crystallized proteins

DISEASE CATEGORY: Inflammation INDICATION: Asthma argenx and VIB have developed antibodies against LGALS10 that could help treat asthma and other allergic airway diseases. Patients with severe asthma had crystals comprising LGALS10 in airway tissue and...
21:21 , Jun 14, 2019 |  BioCentury  |  Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

A string of departures at Novartis AG and strategic shifts by new CEO Vasant Narasimhan have produced a fairly thorough makeover of the executive committee he inherited in 2018. The team gains a pipeline that...
12:35 , May 8, 2019 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: April 2019

New Therapeutic Targets and Biomarkers: April 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during April. Therapeutic targets are defined as any protein, gene or other molecule...
19:27 , Apr 15, 2019 |  BC Innovations  |  Distillery Therapeutics

Inhibitors of allergen-specific IgE responses for peanut allergy

DISEASE CATEGORY: Inflammation INDICATION: Allergy Cell culture studies identified two covalent, heterobivalent inhibitors of IgE responses against Ara h2 and Ara h6 that could help treat peanut allergy. The covalent heterobivalent inhibitors consist of an...
17:10 , Jan 16, 2019 |  BC Innovations  |  Distillery Therapeutics

Inflammation

INDICATION: Allergy Patient sample and mouse studies suggest colonization with Anaerostipes caccae could help treat allergy to cow's milk in infants. In fecal samples from infants with cow's milk allergy, A. caccae counts were higher...
23:52 , Jan 14, 2019 |  BC Extra  |  Preclinical News

ClostraBio identifies gut bacteria species that prevents milk allergy

A team led by Cathryn Nagler, a food allergy professor at the University of Chicago and president and co-founder of ClostraBio Inc. (Chicago, Ill.), has identified a bacterial species that could prevent allergic reaction to...
18:56 , Nov 16, 2018 |  BC Week In Review  |  Company News

ICER: asthma mAbs should be 50% cheaper for cost effectiveness

The Institute for Clinical and Economic Review (ICER) said the costs of five asthma mAbs would need to decrease by at least 50% to be cost effective in a final evidence report . ICER said...
17:57 , Sep 28, 2018 |  BC Week In Review  |  Company News

ICER finds asthma mAbs to be not cost-effective

In a draft evidence report , the Institute for Clinical and Economic Review (ICER) found that five biologics approved or in testing to treat asthma were not cost-effective compared with standard of care (SOC) therapies...
02:44 , Mar 10, 2018 |  BioCentury  |  Product Development

Virtual leap

Novartis AG’s decision to expand a collaboration with mobile technology and clinical trials management company Science 37 Inc. fits squarely within CEO Vasant Narasimhan’s oft-stated plans to use digital health to speed drug development. The...
20:51 , Mar 2, 2018 |  BC Week In Review  |  Clinical News

DBV reports Phase I/II data for milk protein allergy therapy

DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) reported preliminary data from the Phase II portion of the Phase I/II MILES trial to treat IgE-mediated cow’s milk protein allergy showing that the once-daily 300 µg dose of Viaskin...